0.33
+0.0374(+12.72%)
Currency In USD
| Previous Close | 0.29 |
| Open | 0.3 |
| Day High | 0.35 |
| Day Low | 0.3 |
| 52-Week High | 2.54 |
| 52-Week Low | 0.24 |
| Volume | 2.04M |
| Average Volume | 1.18M |
| Market Cap | 13.9M |
| PE | -0.69 |
| EPS | -0.48 |
| Moving Average 50 Days | 0.38 |
| Moving Average 200 Days | 0.7 |
| Change | 0.04 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $18.94 as of December 11, 2025 at a share price of $0.331. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $380.92 as of December 11, 2025 at a share price of $0.331.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
GlobeNewswire Inc.
Yesterday at 1:30 PM GMT
Platform Poised to Expand into Joint and Cartilage RepairHOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending
FibroBiologics Announces Payoff of Outstanding Debt
GlobeNewswire Inc.
Nov 26, 2025 1:30 PM GMT
Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversionsHOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 25, 2025 9:05 PM GMT
HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and pote